On Demand Webcast

Share

Program Content

Activities

  • EBC: Utility of Ki67 Testing
    Optimal Utilization of Ki67 Testing in HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Oncology and Pathology Healthcare Teams
    Multimedia
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 11, 2022

    Expires: May 10, 2023

Faculty

cover img faculity

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Lilly